首頁 > 市場調查報告書 > 製藥

基因治療學和RNAi 基因療法

市場調查報告書

商品編碼

1475212

全球癌症基因治療市場研究報告 - 2024 年至 2032 年產業分析、規模、佔有率、成長、趨勢和預測

Global Cancer Gene Therapy Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年04月01日 | 出版商:

Value Market Research | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球癌症基因治療市場需求預計將從2023年的31.1億美元達到近161億美元的市場規模，2024年至2032年的研究期間複合年成長率為20.05%。

癌症基因治療利用基因技術，透過標靶參與腫瘤生長、進展和存活的特定基因或細胞途徑來治療癌症。這種治療方法旨在修改或抑制癌症相關基因，刺激針對癌細胞的免疫反應，或將治療基因直接傳遞到腫瘤中以抑制其生長或誘導細胞死亡。這種療法有望成為包括實體瘤和血液惡性腫瘤在內的各種類型癌症的潛在治療選擇，與傳統化療和放射療法相比，具有降低毒性的標靶和個人化干涉的潛力。

市場動態

全球範圍內癌症的快速流行和傳統癌症治療的有限療效推動了對基因治療等新型治療方法的需求，基因治療為在基因層面上靶向和精確治療癌症提供了潛力。隨著對癌症生物學、腫瘤異質性和腫瘤發生的分子機制的日益了解，人們越來越重視開發針對特定基因突變、癌基因和與癌症進展有關的訊號通路的基因治療策略。此外，CRISPR/Cas9、TALEN 和鋅指核酸酶等基因編輯技術的出現使得能夠精確修飾癌症相關基因，為開發破壞致癌途徑、增強腫瘤抑制和改善患者預後的基因療法提供了新的機會。

此外，用於基因傳遞的病毒和非病毒載體的不斷增加、載體工程的進步以及基因轉移技術的最佳化推動了更安全、更有效和有針對性的癌症基因治療的發展。此外，對癌症研究、臨床試驗和基因治療產品監管許可的投資不斷增加，促進了癌症基因治療市場的創新和商業化。基因療法具有徹底改變癌症治療模式的潛力，為患有難治性癌症、罕見遺傳性疾病和未滿足的醫療需求的患者帶來了新的希望，推動了人們對這個快速發展的領域的興趣和投資。

然而，嚴格的監管要求、臨床試驗的複雜性和倫理問題可能會挑戰癌症基因治療市場的成長。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球癌症基因治療市場的各個細分市場進行了包容性評估。癌症基因治療產業的成長和趨勢為這項研究提供了整體方法。

市場區隔

癌症基因治療市場報告的這一部分提供了國家和地區層面細分市場的詳細資料，從而幫助策略家確定相應產品或服務的目標人口統計數據以及即將到來的機會。

透過治療

溶瘤病毒療法
基因誘導免疫療法
基因轉移

按最終用途

研究機構
生物製藥公司
診斷中心
其他

區域分析

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲癌症基因治療市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。癌症基因治療市場的主要參與者包括Abeona Therapeutics Inc.、Asklepios BioPharmaceutical Inc.、Altor Bioscience Inc.、Bluebird bio Inc.、BioCancell Inc.、Celgene Inc.、Elevate Bio Inc.、GlaxoSmithKline Inc.、Genelux Corporation、 GenVecec 、Introgen Therapeutics Inc.、Merck KGaA、OncoGenex Pharmaceuticals Inc. 本部分包含競爭格局的整體視圖，其中包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概覽、合作、新產品開發、新產品發布以及其他進展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概覽、歷史與預測資料銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概覽、歷史與預測資料銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區按國家銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 東南亞銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概覽、歷史與預測資料銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲按國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 8 章：癌症基因治療公司的競爭格局

癌症基因治療市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 9 章：公司簡介

頂級公司市佔率分析
市場集中度
Abeona Therapeutics Inc.

公司簡介
公司收入
產品
最近的發展

Asklepios BioPharmaceutical Inc.

公司簡介
公司收入
產品
最近的發展

Altor Bioscience Inc.

公司簡介
公司收入
產品
最近的發展

Bluebird Bio Inc.

公司簡介
公司收入
產品
最近的發展

BioCancell Inc.

公司簡介
公司收入
產品
最近的發展

Celgene Inc.

公司簡介
公司收入
產品
最近的發展

Elevate Bio Inc.

公司簡介
公司收入
產品
最近的發展

GlaxoSmithKline Inc.

公司簡介
公司收入
產品
最近的發展

Genelux Corporation

公司簡介
公司收入
產品
最近的發展

GenVec

公司簡介
公司收入
產品
最近的發展

Introgen Therapeutics Inc.

公司簡介
公司收入
產品
最近的發展

Merck KGaA

公司簡介
公司收入
產品
最近的發展

OncoGenex Pharmaceuticals Inc.

公司簡介
公司收入
產品
最近的發展

註 - 在公司概況中，財務詳細資料和最新進展視情況而定，或對私人公司而言可能不包括在內

簡介目錄圖表

Product Code: VMR112114339

The global demand for Cancer Gene Therapy Market is presumed to reach the market size of nearly USD 16.1 Billion by 2032 from USD 3.11 Billion in 2023 with a CAGR of 20.05% under the study period 2024 - 2032.

Cancer gene therapy uses genetic techniques to treat cancer by targeting specific genes or cellular pathways involved in tumor growth, progression, and survival. This therapeutic approach aims to modify or suppress cancer-related genes, stimulate immune responses against cancer cells, or deliver therapeutic genes directly into tumors to inhibit their growth or induce cell death. This therapy holds promise as a potential treatment option for various types of cancer, including solid tumors and hematological malignancies, offering the potential for targeted and personalized interventions with reduced toxicity compared to traditional chemotherapy and radiation therapy.

MARKET DYNAMICS

The spurring prevalence of cancer worldwide and the limited efficacy of conventional cancer treatments drive the demand for novel therapeutic approaches such as gene therapy, which offers the potential for targeted and precise treatment of cancer at the genetic level. With the growing understanding of cancer biology, tumor heterogeneity, and molecular mechanisms of oncogenesis, there is an increasing emphasis on developing gene therapy strategies that target specific genetic mutations, oncogenes, and signaling pathways implicated in cancer progression. Additionally, the advent of gene editing technologies such as CRISPR/Cas9, TALENs, and zinc finger nucleases enables precise modification of cancer-related genes, offering new opportunities for developing gene therapies that disrupt oncogenic pathways, enhance tumor suppression, and improve patient outcomes.

Moreover, the increasing availability of viral and non-viral vectors for gene delivery, advancements in vector engineering, and optimization of gene transfer techniques drive the development of safer, more efficient, and targeted cancer gene therapy. Furthermore, the growing investment in cancer research, clinical trials, and regulatory clearances for gene therapy products foster innovation and commercialization in the cancer gene therapy market. With the potential to revolutionize cancer treatment paradigms, gene therapy provides new hope for patients with refractory cancers, rare genetic disorders, and unmet medical needs, driving interest and investment in this rapidly evolving field.

However, stringent regulatory requirements, clinical trial complexities, and ethical concerns may challenge the growth of the cancer gene therapy market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of cancer gene therapy. The growth and trends of cancer gene therapy industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the cancer gene therapy market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Therapy

Oncolytic Virotherapy
Gene Induced Immunotherapy
Gene Transfer

By End-Use

Research Institutes
Biopharmaceutical Companies
Diagnostic Centers
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Cancer Gene Therapy market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Cancer Gene Therapy market include Abeona Therapeutics Inc., Asklepios BioPharmaceutical Inc., Altor Bioscience Inc., Bluebird bio Inc., BioCancell Inc., Celgene Inc., Elevate Bio Inc., GlaxoSmithKline Inc., Genelux Corporation, GenVec, Introgen Therapeutics Inc., Merck KGaA, OncoGenex Pharmaceuticals Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. CANCER GENE THERAPY - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Therapy
- 3.7.2 Market Attractiveness Analysis By End-use
- 3.7.3 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL CANCER GENE THERAPY MARKET ANALYSIS BY THERAPY

5.1. Overview By Therapy
5.2. Historical and Forecast Data
5.3. Analysis By Therapy
5.4. Oncolytic Virotherapy Historic and Forecast Sales By Regions
5.5. Gene Induced Immunotherapy Historic and Forecast Sales By Regions
5.6. Gene Transfer Historic and Forecast Sales By Regions

6. GLOBAL CANCER GENE THERAPY MARKET ANALYSIS BY END-USE

6.1. Overview By End-use
6.2. Historical and Forecast Data
6.3. Analysis By End-use
6.4. Research Institutes Historic and Forecast Sales By Regions
6.5. Biopharmaceutical Companies Historic and Forecast Sales By Regions
6.6. Diagnostic Centers Historic and Forecast Sales By Regions
6.7. Others Historic and Forecast Sales By Regions

7. GLOBAL CANCER GENE THERAPY MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1 Overview, Historic and Forecast Data Sales Analysis
- 7.3.2 North America By Segment Sales Analysis
- 7.3.3 North America By Country Sales Analysis
- 7.3.4 United States Sales Analysis
- 7.3.5 Canada Sales Analysis
- 7.3.6 Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1 Overview, Historic and Forecast Data Sales Analysis
- 7.4.2 Europe By Segment Sales Analysis
- 7.4.3 Europe By Country Sales Analysis
- 7.4.4 United Kingdom Sales Analysis
- 7.4.5 France Sales Analysis
- 7.4.6 Germany Sales Analysis
- 7.4.7 Italy Sales Analysis
- 7.4.8 Russia Sales Analysis
- 7.4.9 Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1 Overview, Historic and Forecast Data Sales Analysis
- 7.5.2 Asia Pacific By Segment Sales Analysis
- 7.5.3 Asia Pacific By Country Sales Analysis
- 7.5.4 China Sales Analysis
- 7.5.5 India Sales Analysis
- 7.5.6 Japan Sales Analysis
- 7.5.7 South Korea Sales Analysis
- 7.5.8 Australia Sales Analysis
- 7.5.9 South East Asia Sales Analysis
- 7.5.10 Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1 Overview, Historic and Forecast Data Sales Analysis
- 7.6.2 Latin America By Segment Sales Analysis
- 7.6.3 Latin America By Country Sales Analysis
- 7.6.4 Brazil Sales Analysis
- 7.6.5 Argentina Sales Analysis
- 7.6.6 Peru Sales Analysis
- 7.6.7 Chile Sales Analysis
- 7.6.8 Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1 Overview, Historic and Forecast Data Sales Analysis
- 7.7.2 Middle East & Africa By Segment Sales Analysis
- 7.7.3 Middle East & Africa By Country Sales Analysis
- 7.7.4 Saudi Arabia Sales Analysis
- 7.7.5 UAE Sales Analysis
- 7.7.6 Israel Sales Analysis
- 7.7.7 South Africa Sales Analysis
- 7.7.8 Rest Of Middle East And Africa Sales Analysis

8. COMPETITIVE LANDSCAPE OF THE CANCER GENE THERAPY COMPANIES

8.1. Cancer Gene Therapy Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9. COMPANY PROFILES OF CANCER GENE THERAPY INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Abeona Therapeutics Inc.
- 9.3.1 Company Overview
- 9.3.2 Company Revenue
- 9.3.3 Products
- 9.3.4 Recent Developments
9.4. Asklepios BioPharmaceutical Inc.
- 9.4.1 Company Overview
- 9.4.2 Company Revenue
- 9.4.3 Products
- 9.4.4 Recent Developments
9.5. Altor Bioscience Inc.
- 9.5.1 Company Overview
- 9.5.2 Company Revenue
- 9.5.3 Products
- 9.5.4 Recent Developments
9.6. Bluebird Bio Inc.
- 9.6.1 Company Overview
- 9.6.2 Company Revenue
- 9.6.3 Products
- 9.6.4 Recent Developments
9.7. BioCancell Inc.
- 9.7.1 Company Overview
- 9.7.2 Company Revenue
- 9.7.3 Products
- 9.7.4 Recent Developments
9.8. Celgene Inc.
- 9.8.1 Company Overview
- 9.8.2 Company Revenue
- 9.8.3 Products
- 9.8.4 Recent Developments
9.9. Elevate Bio Inc.
- 9.9.1 Company Overview
- 9.9.2 Company Revenue
- 9.9.3 Products
- 9.9.4 Recent Developments
9.10. GlaxoSmithKline Inc.
- 9.10.1 Company Overview
- 9.10.2 Company Revenue
- 9.10.3 Products
- 9.10.4 Recent Developments
9.11. Genelux Corporation
- 9.11.1 Company Overview
- 9.11.2 Company Revenue
- 9.11.3 Products
- 9.11.4 Recent Developments
9.12. GenVec
- 9.12.1 Company Overview
- 9.12.2 Company Revenue
- 9.12.3 Products
- 9.12.4 Recent Developments
9.13. Introgen Therapeutics Inc.
- 9.13.1 Company Overview
- 9.13.2 Company Revenue
- 9.13.3 Products
- 9.13.4 Recent Developments
9.14. Merck KGaA
- 9.14.1 Company Overview
- 9.14.2 Company Revenue
- 9.14.3 Products
- 9.14.4 Recent Developments
9.15. OncoGenex Pharmaceuticals Inc.
- 9.15.1 Company Overview
- 9.15.2 Company Revenue
- 9.15.3 Products
- 9.15.4 Recent Developments